Cory M. Nadel

This paper identifies a covalent compound EN1441 that selectively degrades AR and AR-V7 in androgen-independent prostate cancer cells by targeting an intrinsically disordered cysteine.

This study determines the structures of CHIP stabilized by Fab antibodies, revealing conformational switches that regulate its E3 ligase and chaperone functions.

The paper demonstrates VIPER-TACs, which use viral E3 ligases to selectively degrade disease-specific proteins, reducing toxicity and expanding therapeutic options for targeted protein degradation.